

RESEARCH

Open Access



Ultrasonographic assessment of enthesal sites of upper and lower extremities in hemodialysis patients using Madrid Sonography Enthesitis Index

Reham Sabry^{1*}, Samar Tharwat² , Mohammed Kamal Nassar³ and Ehab E. Eltoraby²

Abstract

Background: There is no much information about the enthesal involvement among hemodialysis (HD) patients. The aim of this study was to assess the frequency and distribution of ultrasonographic (US) enthesal alterations in HD patients and to evaluate the association between US abnormalities and both clinical and laboratory data.

Methods: This study was conducted on 41 HD patients and 23 sex- and age- matched controls. All participants were evaluated clinically for any signs of enthesopathy. Six entheses sites were scanned bilaterally using grey scale (GS) and power Doppler (PD) US and were scored using Madrid Sonography Enthesitis Index (MASEI) scoring system.

Results: In HD patients, at least one clinical sign suggestive of enthesopathy was found in 69 (14%) of 492 entheses. HD patients had statistically significant higher scores of structural tendon abnormalities ($p < 0.001$), entheses thickening ($p < 0.001$), bone erosions ($p < 0.001$) and calcification ($p = 0.037$) than the healthy controls. Total MASEI score was higher in HD patients than healthy controls (median; 18 vs 8, $p < 0.001$), also, MASEI-inflammatory (median; 11 vs 3, $p < 0.001$) and damage scores (median; 6 vs 0, $p < 0.001$). There was a statistically significant positive association between total MASEI score and both age ($p = 0.032$) and duration of HD ($p = 0.037$). Duration of HD was predictive for both MASEI-damage component ($p = 0.004$) and total MASEI score ($p = 0.014$).

Conclusion: There is a high prevalence of subclinical enthesopathy in HD patients. The enthesal US alterations is much higher in HD patients than in healthy subjects. The duration of HD is the significant predictor of enthesopathy in HD patients.

Keywords: Ultrasonography, Enthesitis, Enthesopathy, Hemodialysis, MASEI score

Introduction

Chronic kidney disease (CKD) affects about 10–15% of adults worldwide [1]. And therefore, end stage kidney disease (ESKD) represents a global-health and health-care burden that is rapidly increasing [2]. The high

prevalence of diabetes mellitus, hypertension, obesity, and ageing are all contributing to the global rise in this condition [3]. Dialysis is a form of renal replacement therapy that ensures maintenance of homeostasis in patients with ESRD [4]. Currently, dialysis is life-saving to nearly 3.4 million people with ESRD around the world [5]. Hemodialysis (HD), peritoneal dialysis, and hemofiltration are the three main forms of dialysis [6].

Although HD can reduce morbidity and mortality in renal patients, it can also cause a number of

*Correspondence: dr_rehamsabry88@yahoo.com

¹ Nephrology unit, Internal Medicine Department, Mansoura New General Hospital, Mansoura University, Mansoura, Egypt
Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

complications during dialysis sessions and/or as a result of long-term HD use [7]. Amyloidosis, bone disease, endocrine abnormalities, infection and cardiovascular complications are all risks associated with long-term HD [7]. Musculoskeletal (MSK) complications are one of the most common health concerns that impact individuals on maintenance HD [8]. Bone cysts, destructive arthropathy, amyloidosis, carpal tunnel syndrome, and spontaneous tendons rupture are some of these MSK complications [9, 10].

In HD patients, spontaneous ruptures of the Achilles and/or quadriceps tendon have been documented on a sporadic basis and are usually viewed as isolated events [11]. The reasons that predispose to such ruptures are still unknown. Some researchers believe that the tendon is still intact and that the rupture is caused by osteolytic bone resorption at the enthesis [12]. Enthesis is the area where ligaments, tendons, or joint capsules attach to bone [13].

Ultrasonography (US) is a widely available, noninvasive, reproducible, low-cost imaging modality that does not expose patients to ionizing radiation and can be used to diagnose, monitor, and stratify enthesopathy. When it comes to diagnosing enthesopathy, US is more sensitive than clinical examination, demonstrating a high frequency of abnormal findings even in asymptomatic patients [14]. However, little information is known about the enthesal involvement in HD patients; only few studies have been carried out to assess if HD patients have a 'subclinical' enthesopathy [15, 16]. In some clinical contexts, such as in cases of "difficult to treat" pain syndromes, an early diagnosis of enthesal involvement may be crucial. Therefore, the aim of this study was to evaluate the frequency and distribution of enthesal US alterations in HD patients and to evaluate the association between US findings and both clinical characteristics and laboratory data.

Materials and methods

Study population

This cross-sectional observational study was carried out from October 2017 to March 2020 on 41 patients with ESRD and receiving HD at Mansoura Nephrology and Dialysis Unit (MNDU), Mansoura University Hospital, Egypt. The sample size was selected as a convenience sample. All patients who met the inclusion criteria were offered to participate in the study unless they qualify for any of the exclusion criteria or refuse to participate. Inclusion criteria included ESRD patients aged more than 18 years and undergoing HD for more than 6 months, three times per week. Patients who had a history of rheumatic or autoimmune diseases, diabetes mellitus, peripheral neuropathy, chronic use of steroids

and/ or fluoroquinolone therapy during the previous 6 months, severe trauma or joint surgery were excluded from the study. Twenty-three age- and sex matched healthy controls were also included. The study was performed in accordance with the Declaration of Helsinki. It was approved by the Institutional Research Board of the Faculty of Medicine, Mansoura University (Approval number: MS/17.05.120). The study was explained to all participants, and informed written consent was obtained from all of them before starting the study.

Data collection

Demographic data including age, sex, occupation, and marital status were recruited. Body weight was measured. Other clinical parameters (e.g., vascular access side and HD duration) were obtained from each HD patient through an interview.

Clinical evaluation of different enthesal sites

Clinical evaluation was conducted to all HD patients and healthy controls by an expert rheumatologist to detect any clinical signs indicative of enthesopathy. These signs included swelling or tenderness elicited by mobilization, pressure, and contraction against resistance of the corresponding entheses.

Madrid sonographic Enthesis index (MASEI) scoring system

All US examinations were carried out by a rheumatologist with at least 7 years of experience in the field of musculoskeletal ultrasound (MSUS). At the time of US evaluation, the rheumatologist was blind to the clinical assessment of the enthesal sites. The EDAN U2 ultrasound equipment (Shenzhen, China) with a linear array transducer was employed in the study (8 to 13.4 MHz). The frequency was set to 13 MHz, and the sonographic settings were adjusted to provide the best images of the scanned enthesis. With a constant room temperature of 21 °C and a lower wall filter, power Doppler (PD) settings were standardized with a pulse repetition frequency (PRF) of 0.75–1.20 kHz and a PD gain of 50–55 dB.

Six entheses were scanned bilaterally in axial and longitudinal planes as specified by de Miguel [17]. The scanned enthesal sites included the following: proximal plantar aponeurosis, distal Achilles' tendon, distal and proximal patellar ligament insertion, distal quadriceps tendon and distal triceps tendon. Enteses were scored using the Madrid Sonography Enthesitis Index (MASEI) scoring system [17]. The elementary lesions included thickness, structural tendon abnormalities, enthesitis thickening, bone erosions, calcification, PD and bursitis. Tendon structure was defined as abnormal if hypoechoic aspect, loss of fibrillar pattern or fusiform thickening of the enthesis occurred. Thicknesses of ligaments, tendons,

and fascia were determined on the axial scan as the maximum anteroposterior diameter in millimeters, excluding the paratenon at the point of maximum thickness proximal to the bony insertion.

Additionally, analysis 2 subscores of MASEI were included; the MASEI-inflammatory (structural tendon abnormalities, enthesis thickening, PD and bursitis) and MASEI-damage (calcifications, enthesophytes, and erosions) [18].

Blood sampling and laboratory tests

Just before starting the first HD session of the week, blood samples were taken from the vascular access of HD patients. An automated analyzer was used to perform laboratory tests on the days of blood sampling. Laboratory tests included complete blood count (CBC), total cholesterol, triglycerides, serum calcium, phosphorus, parathyroid hormone level (PTH) and uric acid.

Statistical analysis

Data were collected, and analyzed using IBM SPSS Statistics version 24.0 for Windows (IBM Corp., Armonk, NY, USA) on a personal computer. For all quantitative values, medians (interquartile range [IQR] or 25th percentile – 75th percentile) or means ± standard deviation were used, while numbers of cases and percentages (%) were utilized to illustrate qualitative variables. The Shapiro-Wilk test was used to check for normality in the distribution of continuous variables and the significance of differences between the two groups was assessed by the independent samples t test for normally distributed variables or by the Mann-Whitney test for non-parametric variables. For comparisons between qualitative variables, Chi-square or Fisher exact tests were utilized, as appropriate. An analysis of covariance (ANCOVA) test was used to determine the effect of HD on MASEI score assuming age as a covariate. Correlation analysis using the Spearman’s test were used to define relevant factors that affected MASEI scores. Subsequently, univariate linear regression analysis was done to assess the predictors of MASEI scores. P value less than 0.05 was considered significant.

Results

Study population

The study included a total of 41 HD patients (mean age 50.7 ± 14.5 years, 25 males and 16 females) and 23 healthy sex- and age-matched controls (mean age 45.3 ± 8.9 years, 14 males and 9 females). We scanned 492 entheses sites in HD patients and 276 in healthy controls. Table 1 shows the clinical characteristics and laboratory data of HD patients and healthy controls. For the HD group, the

Table 1 Clinical characteristics and laboratory data of HD patients (n = 41) and healthy subjects (n = 23)

Characteristic	HD patients (n = 41)	Healthy subjects (n = 23)	P
Age (years)	50.7 ± 14.5	45.3 ± 8.9	0.068
Sex			
Males	25 (61%)	14 (60.9%)	0.993
Females	16 (39%)	9 (39.1%)	
Body weight (Kg)	73 (63–78.8)	77 (70–80)	0.266
Occupation			
Not working	22 (53.7)	18 (78.3)	0.051
Working	19 (46.3)	5 (21.7)	
Marital status			
Single	9 (22)	10 (43.5)	0.053
Married	32 (78)	13 (56.5)	
Duration of HD (years)	4 (2–6)	–	–
Vascular access			
Right side	8 (19.5)	–	–
Left side	33 (80.5)	–	–
Hemoglobin (g/dL)	9.9 (9.2–10.9)	N/A	–
Cholesterol (mg/dL)	110 (93–130.5)	N/A	–
Triglycerides (mg/dL)	73 (63–104.5)	N/A	–
Calcium (mg/dL)	8.5 (7–9.5)	N/A	–
Phosphorus (mg/dL)	6 (3.6–8.5)	N/A	–
PTH (pg/mL)	518 (207–1090.5)	N/A	–
Uric acid (mg/dl)	6.4 (5.4–7)	N/A	–

Quantitative variables are expressed as mean ± standard deviation for normally distributed data and median (25th percentile – 75th percentile) for non-normally distributed data. Qualitative variables are expressed as number (%)

PTH Parathyroid hormone

median duration since onset of HD was 4 years. Majority of patients (80.5%) had vascular access at the right side.

Clinical evaluation of different enthesal sites

Clinical examination revealed at least one sign suggestive of enthesopathy in 69 (14.02%) of 492 entheses in 41 HD patients. Of which, the most frequently involved enthesal site was proximal patellar ligament (19.5%) followed by quadriceps tendon (18.3%) while the least involved was triceps tendon enthesis (2.4%). No clinical evidence of enthesopathy was detected in healthy controls. Figure 1 shows the distribution of enthesal sites that clinically involved in HD patients.

Madrid sonographic Enthesis index (MASEI) scoring system

Table 2 illustrates the morphostructural changes of each enthesis according to MASEI scoring system. HD patients had significantly higher thickness and structural tendon abnormalities at almost all scanned enthesal sites when compared to healthy individuals.




Table 3 shows the total MASEI scores of each component and each enthesis in HD patients and healthy subjects. There were statistically significant higher scores of structural tendon abnormalities ($p < 0.001$), enthesis thickening ($p < 0.001$), bone erosions ($p < 0.001$) and calcification ($p = 0.037$) in HD patients when compared with healthy subjects. Also, total MASEI score of each enthesis was significantly higher in HD patients in comparison to healthy subjects. HD patients had significantly higher total MASEI score than healthy controls (median; 18 vs 8, $p < 0.001$), also higher MASEI-inflammatory (median; 11 vs 3, $p < 0.001$) and damage scores (median; 6 vs 0, $p < 0.001$). There was a significant effect of HD on the total and inflammatory MASEI score ($p = 0.012, 0.011$, respectively) after controlling for the effect of age.

Of a total 492 scanned enthesal sites in 41 HD patients, the highest number of elemental lesions seen was enthesis thickening (272/492, 55.3%), followed by structural tendon abnormalities (158/492, 32.1%), calcification (69/492, 14%), bone erosions (66/492, 13.4%), bursitis (14/492, 2.8%) and power Doppler signal (40/492, 8%) as shown in Table 4.

Figure 2 illustrates calcification at the posterior pole of calcaneus enthesis detected in a HD patient and Fig. 3 shows deep infrapatellar bursitis in another HD patient.

Correlation between MASEI scores and clinico-laboratory data

As shown in Table 5, there was a statistically significant positive association between total MASEI score and both age ($p = 0.032$) and duration of HD ($p = 0.037$). However, no statistically significant correlation was found between total MASEI, MASEI-inflammatory, and MASEI-damage scores and the following variables: body weight, total cholesterol, serum calcium, phosphorous and parathyroid hormone levels.

Predicting MASEI scores in HD patients

Univariate regression analyses revealed the following data: age was predictive for MASEI-inflammatory component ($p = 0.042$) while duration of HD was predictive for both MASEI-damage component ($p = 0.004$) and total MASEI score ($p = 0.014$) as illustrated in Table 6.

Discussion

MSK manifestations are common in patients on long-term HD, with reported frequency up to 70% [19], most of which are attributable to amyloid deposition [19]. Amyloid deposits in a variety of tissues, with a higher proclivity for bone and synovial membranes.

Table 2 The morphostructural changes of each entheses according to Madrid Sonographic Enthesis Index (MASEI) Scoring System in HD patients ($n = 41$) and healthy subjects ($n = 23$)

Parameter	HD patients ($n = 41$) Entheses (82)	Healthy controls ($n = 23$) Entheses =46	P
Inferior pole of the calcaneus: plantar aponeurosis entheses			
Thickness,mm, median (IQR)	4.3 (1.35)	3.15 (1.6)	0.000*
Structural tendon abnormalities,n (%)	46 (56.1)	14 (30.4)	0.005*
Enthesis thickening,n (%)	36 (43.9)	7 (15.2)	0.001*
Bone erosions,n (%)	5 (6.1)	1 (2.2)	0.418
Calcification,n (%)			
Mild	2 (2.4)	0	0.104
Moderate	14 (17.1)	3 (6.5)	
Severe	3 (3.7)	5 (10.9)	
Power Doppler signal,n (%)	0	0	–
Superior pole of the calcaneus: Achilles tendon entheses			
Thickness,mm, median (IQR)	5.2 (1.53)	4.1 (1.3)	0.000*
Structural tendon abnormalities,n (%)	16 (19.5)	4 (8.7)	0.132
Enthesis thickening,n (%)	40 (48.8)	6 (13)	0.000
Retrocalcaneal bursitis	10 (12.2)	3 (6.5)	0.375
Bone erosions,n (%)	10 (12.2)	0	0.014*
Calcification,n (%)			
Mild	6 (7.3)	1 (2.2)	0.208
Moderate	8 (9.8)	2 (4.3)	
Severe	0	1 (2.2)	
Power Doppler signal,n (%)	0	0	–
Tibial tuberosity: distal patellar ligament entheses			
Patellar ligament structure,n (%)	55 (67.1)	13 (28.3)	0.000*
Thickness,mm, median (IQR)	4.45 (1.6)	3.4 (0.85)	0.000*
Structural tendon abnormalities,n (%)	27 (32.9)	2 (4.3)	0.000*
Enthesis thickening,n (%)	50 (61)	10 (21.7)	0.000*
Infrapatellar bursitis,n (%)	4 (4.9)	2 (4.3)	1
Bone erosions,n (%)	7 (8.5)	1 (2.2)	0.257
Calcification,n (%)			
Mild	4 (4.9)	0	0.401
Moderate	2 (2.4)	1 (2.2)	
Severe	1 (1.2)	0	
Power Doppler signal,n (%)	0	0	–
Inferior pole of the patella: proximal patellar ligament entheses			
Thickness,mm, median (IQR)	4.55 (1.23)	3.5 (1.33)	0.000*
Structural tendon abnormalities,n (%)	18 (22)	4 (8.7)	0.086
Enthesis thickening,n (%)	55 (67.1)	13 (28.3)	0.000*
Bone erosions,n (%)	4 (4.9)	1 (2.2)	0.654
Calcification,n (%)			
Mild	1 (1.2)	1 (2.2)	0.693
Moderate	1 (1.2)	0	
Severe	0	0	
Power Doppler signal,n (%)	0	0	–
Superior pole of the patella: quadriceps tendon entheses			
Thickness,mm, median (IQR)	6.4 (1.7)	6 (1.53)	0.002*
Structural tendon abnormalities,n (%)	36 (43.9)	9 (19.6)	0.006*
Enthesis thickening,n (%)	56 (86.3)	19 (41.3)	0.003*
Bone erosions,n (%)	28 (34.1)	4 (8.7)	0.001*

Table 2 (continued)

Parameter	HD patients (n = 41) Entheses (82)	Healthy controls (n = 23) Entheses = 46	P
Calcification, n (%)			
Mild	7 (8.5)	2 (4.3)	0.218
Moderate	11 (13.4)	2 (4.3)	
Severe	1 (1.2)	0	
Power Doppler signal, n (%)	3 (3.7)	0	0.552
Olecranon tuberosity: triceps tendon enthesis			
Thickness, mm, median (IQR)	4.05 (2.43)	2.7 (1.03)	0.000*
Structural tendon abnormalities, n (%)	15 (18.3)	1 (2.2)	0.010*
Enthesis thickening, n (%)	35 (42.7)	0	0.000*
Bone erosions, n (%)	12 (14.6)	1 (2.2)	0.031*
Calcification, n (%)			
Mild	6 (7.3)	0	0.091
Moderate	2 (2.4)	0	
Power Doppler signal, n (%)	1 (1.2)	0	1

*p < 0.05

Table 3 The total MASEI scores of each component and each enthesis in HD patients (n = 41) and healthy subjects (n = 23)

Enthesis	HD patients (n = 41) Entheses (82) median (IQR)	Healthy controls (n = 23) Entheses = 46 median (IQR)	P
MASEI components score (maximum score)			
Structural tendon abnormalities (12)	4 (3)	1 (3)	0.000*
Enthesis thickening (12)	7 (3)	1 (3)	0.000*
Bursitis (4)	0 (0)	0 (0)	0.632
Bone erosions (36)	3 (6)	0 (0)	0.000*
Calcification (36)	2 (5)	0 (2)	0.037*
Power Doppler signal (36)	0 (0)	0 (0)	0.187
Total MASEI score at:			
Plantar aponeurosis enthesis	3 (4)	0 (4)	0.015*
Achilles tendon enthesis	2 (5)	0 (1)	0.003*
Distal patellar ligament enthesis	2 (3)	1 (1)	0.000*
Proximal patellar ligament enthesis	2 (2)	1 (1)	0.001*
Quadriceps tendon enthesis	4 (7)	1 (3)	0.000*
Triceps tendon enthesis	1 (3)	0	0.000*
Total MASEI score	18 (11.5)	4 (8)	0.000*
MASEI-inflammatory	11 (7)	3 (5)	0.000*
MASEI-damage	6 (9)	0 (2)	0.000*

Additionally, tendons and peripheral nerves can be impacted by this serious condition [20].

Enthesitis is a common feature of spondylarthritis [21]. However, the clinical examination and radiology used


to evaluate entheses are not reliable nor accurate [22]. High-resolution US is commonly employed as an imaging tool in the diagnosis of enthesopathy [23]. Subclinical enthesal involvement in HD patients has not been deeply investigated [15]. As a result, this study was carried out to identify enthesal involvement in HD patients using MASEI scoring system. Gutierrez and coworkers conducted a similar study utilizing Glasgow Ultrasound Enthesitis Scoring System (GUESS), although it does not include PD evaluation or upper limb enthesal characteristics [15].

Our study sheds new light on the topography and prevalence of enthesal involvement in HD patients. To the best of our knowledge, this is the first to use MASEI scoring system in HD patients. Six enthesal sites were scanned using both GS and PDUS. Clinical examination revealed at least one sign suggestive of enthesopathy in 69 (14.02%) of 492 entheses in 41 HD patients. Musculoskeletal US (MSUS) revealed that tendon and ligament thicknesses were significantly higher in HD patients in comparison to healthy controls. Total MASEI score was positively correlated with both age and duration of HD. Age was predictive for MASEI-inflammatory component while duration of HD was predictive for both MASEI-damage component and total MASEI score.

MSUS can effectively screen for subclinical enthesopathy [24]. Chronic subclinical enthesopathy may diminish tendon mechanical resistance, thus representing a potential risk factor for tendon rupture in the future [25]. In the current study, clinical examination revealed at least one sign suggestive of enthesopathy in 69 (14.02%) of 492 entheses in 41 HD patients, which is much lower than that detected by US (68.9%). A similar pattern of

Table 4 Frequency of involvement of MASEI score components in HD patients ($n = 41$) and healthy subjects ($n = 23$)

MASEI score components	HD patients ($n = 41$) Entheses = 492 n (%)	Healthy controls ($n = 23$) Entheses = 276 n (%)	P
Structural tendon abnormalities	158 (32.1)	34 (12.3)	0.000*
Enthesis thickening	272 (55.3)	55 (19.9)	0.000*
Bursitis	14 (2.8)	5 (1.8)	0.364
Bone erosions	66 (13.4)	8 (2.9)	0.000*
Calcification	69 (14)	18 (6.5)	.002*
Power Doppler signal	4 (0.8)	0	0.303
Presence of one sign of enthesopathy	339 (68.9)	85 (30.8)	0.000*

**Fig. 2** A 60-year-old female patient with chronic renal failure on chronic hemodialysis for 5 years with calcification at the posterior pole of calcaneus enthesis**Fig. 3** A 42-year-old male patient with chronic renal failure on chronic hemodialysis for 6 years with deep infrapatellar bursitis

results was obtained in another study, in which, US signs of enthesopathy were detected in 50% of the scanned enthesal sites in dialysis patients [15]. A high prevalence of subclinical enthesopathy has also been recognized in Behçet's disease [26], Sjögren syndrome [27], fibromyalgia [27], psoriasis [28] and systemic sclerosis [29].

In this study, there were statistically significant higher scores of structural tendon abnormalities, enthesis thickening, bone erosions and calcification in HD patients when compared with healthy subjects. HD patients had significantly higher total MASEI score than healthy controls, also higher MASEI-inflammatory and damage scores. Overall these findings are in accordance with

findings reported by Gutierrez and colleagues in a study conducted on 33 dialysis patients and 33 healthy controls adopting GUESS scoring system and demonstrated a higher prevalence of enthesopathy in dialysis patients than in healthy subjects [15]. Tendon abnormalities in the form of calcific deposition, increased thickness and abnormal peritendon tissue have also been documented in another study, in which, quadriceps and Achilles tendons were evaluated in 50 HD patients by MSUS [30]. The uremic state causes the gradual retention of a significant number of molecules known as uremic retention solutes, which are poisons that would typically be discharged by healthy kidneys. Although the precise role of toxins such indoxyl sulphate and osteoprotegerin has yet to be determined. They have the ability to alter bone metabolism in patients with renal failure as well as, most likely, collagen metabolism.

Our results demonstrate a statistically significant positive association between total MASEI score and both patients' age and duration of HD. A similar conclusion was reached by another study [15]. Age may influence the biological milieu and tendon adaptation to mechanical loading [31]. Additionally, long-term dialysis has been linked to MSK problems, including bone cysts, amyloidosis, destructive arthropathy, carpal tunnel syndrome, and spontaneous tendon rupture [32]. Contrary to the findings of Falsetti and colleagues [33], we did not find a significant association between total MASEI score and body weight.

Tendon degeneration is often caused by metabolic disorders (e.g. diabetes, hyperuricemia, or hypercholesterolemia) [31]. Hypercholesterolemia may be associated with abnormal tendon thickness or structure [34]. However, no correlation was found between MASEI scores and total cholesterol level in our cohort.

Significant osteolytic bone resorption with osteoclasts at the point of tendon insertion has been described in hyperparathyroidism in HD patients

Table 5 Correlation between MASEI scores and clinico-laboratory data among HD patients (N=41)

Variable	MASEI-inflammatory		MASEI-damage		Total MASEI	
	r _s	P	r _s	P	r _s	P
Age (years)	0.297	0.059	0.261	0.099	0.336	0.032*
Sex	0.216	0.175	-0.064	0.693	0.055	0.733
Body weight (Kg)	0.128	0.427	-0.057	0.725	0.029	0.855
Duration of HD (years)	0.171	0.284	0.341	0.029	0.327	0.037*
Associated comorbidities	-0.052	0.745	0.099	0.539	0.029	0.856
Hemoglobin (g/dL)	-0.205	0.199	-0.240	0.130	-0.216	0.176
Cholesterol (mg/dL)	-0.275	0.105	0.128	0.424	-0.036	0.822
Triglycerides (mg/dL)	-0.106	0.510	-0.112	0.485	-0.134	0.403
Calcium (mg/dL)	-0.214	0.180	0.066	0.682	-0.082	0.610
Phosphorus (mg/dL)	0.047	0.770	0.284	0.072	0.139	0.385
PTH (pg/mL)	0.139	0.386	0.076	0.639	0.131	0.414
Uric acid (mg/dl)	0.106	0.511	0.147	0.358	0.138	0.388

*P<0.05,PTH: Parathyroid hormone

Table 6 Univariate regression analysis to identify the predictors for MASEI scores among HD patients (n = 41)

Predictor variable	MASEI-inflammatory		MASEI-damage		Total MASEI	
	B	P	B	P	B	P
Age (years)	0.094	0.042*	0.062	0.357	0.156	0.086
Duration of HD	0.157	0.485	0.875	0.004*	1.032	0.014*
Hemoglobin level (g/dl)	-0.001	0.998	-0.597	0.278	-0.597	0.43
Serum cholesterol (mg/dl)	-0.021	0.164	0.010	0.639	-0.011	0.716
Serum phosphorus (mg/dl)	0.82	0.783	0.391	0.349	0.473	0.409

*P<0.05

[35]. A thickened and degenerated tendon overlying an underlying uremic disease should be recognized and treated as a more advanced form of uremic tendinopathy. Secondary hyperparathyroidism may lead to tendon rupture due to changes that occur at the tendosseous junction [36]. Even though, our results suggest no correlation between MASEI scores and PTH level.

Using univariate linear regression analysis, age was predictive for MASEI-inflammatory component. This is consistent with what has been found in a recent study [37], they investigated the contributing factors of US lesions of entheses in healthy subjects and found that age predicted not only inflammation, but also, damage and total US enthesopathy scores. While the ability of the tendons to compensate for stress is preserved in youth, impaired resilience of aged tissues is connected to cellular senescence and changes in extracellular matrix mechanical properties [38].

One of the strengths of this study is that it represents a comprehensive scanning of entheses at both upper

and lower limbs in HD patients. Also, a control group of sex- and age-matched participants was included. However, our study has some limitations: firstly, the relatively small sample size; sample size calculation was not made according to the primary outcome measurement. Secondly, the cross-sectional nature resulting in only a single evaluation of the entheses with absence of long-term follow-up. Finally, only one sonographer was utilized; a second sonographer would aid in determining the reproducibility of findings because US is an operator-dependent examination with possible inter-observer variability. A future study's goal would be to determine inter and intra reader variability.

To the best of our knowledge, this is the first study to use the MASEI scoring system to detect enthesopathy in HD patients. In conclusion, there is a high prevalence of asymptomatic subclinical enthesopathy in both upper and lower limbs in HD patients. Additionally, the burden of enthesal US alterations is much higher than in healthy subjects. MSUS can be helpful in the early detection of

enthesal abnormalities in HD patients. The duration of HD is the significant predictor of enthesopathy in these patients. Finally, enthesal involvement in HD patients do not correlate with PTH or serum calcium level. The current findings need to be replicated in other ethnic groups and with a larger sample size.

Acknowledgements

Not applicable.

Authors' contributions

Conceptualization: RS, ST, EE Investigation, all authors Data curation, formal analysis: RS, ST, MK, writing—original draft: ST, EE, writing—review & editing: All authors.

Authors' information

Reham Sabry, Specialist, Nephrology unit, Internal Medicine Department, Mansoura New General Hospital, Mansoura University, Egypt.
Samar Tharwat, Associate professor, Rheumatology & Immunology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Egypt <https://orcid.org/0000-0001-9892-2449>
Mohammed Kamal Nassar, Associate professor, Mansoura Nephrology & Dialysis Unit (MNDU), Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt <https://orcid.org/0000-0002-5124-2507>
Ehab E Eltoraby, Professor, Rheumatology & Immunology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Egypt <https://orcid.org/0000-0003-4183-7475>

Funding

Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

Availability of data and materials

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study was performed in accordance with the Declaration of Helsinki. It was approved by the Institutional Research Board of the Faculty of Medicine, Mansoura University (Approval number: MS/17.05.120). The study was explained to all participants, and informed written consent was obtained from all of them before starting the study.

Consent for publication

Not Applicable.

Competing interests

All authors have no conflicts of interest to declare.

Author details

¹Nephrology unit, Internal Medicine Department, Mansoura New General Hospital, Mansoura University, Mansoura, Egypt. ²Rheumatology & Immunology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, El Gomhouria St, Mansoura, Dakahlia Governorate 35511, Egypt. ³Mansoura Nephrology & Dialysis Unit (MNDU), Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

Received: 9 November 2021 Accepted: 1 June 2022

Published online: 23 June 2022

References

- Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. *JAMA*. 2007;298:2038–47.

- Thurlow JS, Joshi M, Yan G, et al. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. *Am J Nephrol*. 2021;52:98–107.
- Thomas MC, Cooper ME, Zimmet PJRN. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. *Nat Rev Nephrol*. 2016;12:73–81.
- Canaud B, Collins A, Maddux F. The renal replacement therapy landscape in 2030: reducing the global cardiovascular burden in dialysis patients. *Nephrol Dial Transplant*. 2020;35:ii51–7.
- Stenvinkel P, Fouque D, Wanner C. *Life/2020—the future of kidney disease*: Oxford University Press; 2020.
- Nitta K, Goto S, Masakane I, et al. Annual dialysis data report for 2018, JSDT renal data registry: survey methods, facility data, incidence, prevalence, and mortality. *Ren Replace Ther*. 2020;6:1–18.
- Scarpioni R, Ricardi M, Albertazzi V, et al. Dialysis-related amyloidosis: challenges and solutions. *Int J Nephrol Renovasc Dis*. 2016;9:319.
- Ezzat S, Tharwat S, Abdelsalam S, Eltoraby EE. Musculoskeletal symptoms in hemodialysis patients and their effect on health-related quality of life. *Blood Purif*. 2020;49:289–94.
- Kiss E, Keusch G, Zanetti M, et al. Dialysis-related amyloidosis revisited. *AJR Am J Roentgenol*. 2005;185:1460–7.
- Tharwat S, Nassar MK. Clinical and ultrasonographic screening for carpal tunnel syndrome in hemodialysis patients *Kidney. Res Clin Pract*. 2020;39:213.
- Kandemir NG, Aydin E, Yalbuздаğ ŞA, et al. Bilateral quadriceps and concomitant unilateral triceps tendon rupture in a chronic hemodialysis patient. *Turk Osteoporoz Dergisi*. 2018;24:104.
- Wani N, Malla H, Kosar T, Dar IM. Bilateral quadriceps tendon rupture as the presenting manifestation of chronic kidney disease. *Indian J Nephrol*. 2011;21:48.
- Liew MY, Mortimer JW, Paxton JZ, Tham S, Rust PAJJoWS. Histomorphology of the subregions of the Scapholunate interosseous ligament and its Enthesis. *J Wrist Surg*. 2021;10:467–75.
- Zuliani F, Zabotti A, Errichetti E, et al. Ultrasonographic detection of subclinical enthesitis and synovitis: a possible stratification of psoriatic patients without clinical musculoskeletal involvement. *Clin Exp Rheumatol*. 2019;37:593–9.
- Gutierrez M, Zeiler M, Filippucci E, et al. Sonographic subclinical enthesal involvement in dialysis patients. *Clin Rheumatol*. 2011;30:907–13.
- Lin CH, Shiang JC, Tsai MK, Chang CC, Chang DM. Sonographic evaluation of lower-limbs Entheses in subclinical patients undergoing hemodialysis. *Formosan J Rheumatol*. 2012;26:41–8.
- de Miguel E, Cobo T, Muñoz-Fernández S, et al. Validity of enthesitis ultrasound assessment in spondyloarthritis. *Ann Rheum Dis*. 2009;68:169–74.
- Macía-Villa C, Cruz Valenciano A, De Miguel E. Enthesis lesions are associated with X-ray progression in psoriatic arthritis. *Int J Rheum Dis*. 2021;24:828–33.
- Akasbi N, Houssaini TS, Tahiri L, et al. Rheumatic complications of long term treatment with hemodialysis. *Rheumatol Int*. 2012;32:1161–3.
- Kelly A, Apostle K, Sanders D, Bailey H. Musculoskeletal pain in dialysis-related amyloidosis. *Can J Surg*. 2007;50:305.
- Schett G, Lories RJ, D'Agostino M-A, et al. Enthesitis: from pathophysiology to treatment. *Nat Rev Rheumatol*. 2017;13:731–41.
- D'Agostino M-AJ. Enthesitis detection by ultrasound: where are we now. *Clin Exp Rheumatol*. 2018;36:127–30.
- Zhu L, Chen P, Sun X, Zhang S. Musculoskeletal ultrasound for ankylosing spondylitis: a systematic review and meta-analysis. *Medicine (Baltimore)*. 2021;100:e25822.
- Vyas K, Jain SK, Mittal A, Kumar R, Saxena S, Malviya S. Sonographic evaluation of subclinical Enthesopathy in patients of chronic plaque psoriasis. *Indian Dermatol Online J*. 2020;11:580–5.
- Di Matteo A, Filippucci E, Cipolletta E, et al. Enthesal involvement in patients with systemic lupus erythematosus: an ultrasound study. *Rheumatology (Oxford)*. 2018;57:1822–9.
- Ozkan F, Cetin GY, Bakan B, et al. Sonographic evaluation of subclinical enthesal involvement in patients with Behçet disease. *AJR Am J Roentgenol*. 2012;199:W723–9.
- Sag S, Sag MS, Tekeoglu I, Kamanlı A, Nas K. Presence of enthesopathy in patients with primary Sjogren's syndrome: ultrasonographic study of a local cohort. *J Med Ultrason*. 2018;45:121–7.

28. Moshrif A, Mosallam A. Subclinical enthesopathy in patients with psoriasis and its association with other disease parameters: a power Doppler ultrasonographic study. *Eur J Rheumatol*. 2017;4:24.
29. Kilic E, Kilic G, Akgul O, Ozgocmen S. Presence of enthesopathy demonstrated with ultrasonography in systemic sclerosis. *Mod Rheumatol*. 2015;25:731–6.
30. Hussein DA, El-Azizi NO, Meged AHA, et al. Ultrasonographic tendon alteration in relation to parathyroid dysfunction in chronic hemodialysis patients. *Clin Med Insights Arthritis Musculoskelet Disord*. 2015;8:CMAMD S20887.
31. Abate M, Schiavone C, Salini V, Andia IJR. Occurrence of tendon pathologies in metabolic disorders. *Rheumatology (Oxford)*. 2013;52:599–608.
32. Shiota E, Tsuchiya K, Yamaoka K, Kawano OJCO, Research R. Spontaneous major tendon ruptures in patients receiving long-term hemodialysis. *Clin Orthop Relat Res*. 2002;394:236–42.
33. Falsetti P, Conticini E, Baldi C, Bardelli M, Cantarini L, Frediani BJRC. Diffuse peripheral Enthesitis in metabolic syndrome: a retrospective clinical and power Doppler ultrasound study. *Reumatol Clin (Engl Ed)*. 2021;S1699-258X:00032.
34. Abate M, Di Carlo L, Salini V, Schiavone C. Metabolic syndrome associated to non-inflammatory Achilles enthesopathy. *Clin Rheumatol*. 2014;33:1517–22.
35. Chen C-M, Wang S-J, Wu S-S, Chu P, Huang GS. Spontaneous rupture of the patellar and contralateral quadriceps tendons associated with secondary hyperparathyroidism in a patient receiving long-term dialysis. *J Formos Med Assoc*. 2006;105:941–5.
36. Tsourvakas S, Gouvalas K, Gimtsas C, et al. Bilateral and simultaneous rupture of the triceps tendons in chronic renal failure and secondary hyperparathyroidism. *Arch Orthop Trauma Surg*. 2004;124:278–80.
37. Bakirci S, Solmaz D, Stephenson W, Eder L, Roth J, Aydin SZ. Enteseal changes in response to age, body mass index, and physical activity: an ultrasound study in healthy people. *J Rheumatol*. 2020;47:968–72.
38. Masi AT, Andonian B, van der Heijde D. Biomechanical factors may be the main contributor to enteseal changes in normal adults. *J Rheumatol*. 2021;48:618–9.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

